Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists are studying a new medicine called CC-92328 to see if it is safe and can help people with a type of cancer called multiple myeloma that has come back after treatment. The study has two parts: one where they test different doses of the medicine and another where they test how well the medicine works.
Scientists are studying a new medicine called CC-92328 to see if it is safe and can help people with a type of cancer called multiple myeloma that has come back after treatment. The study has two parts: one where they test different doses of the medicine and another where they test how well the medicine works.
*Third Opinion AI Generated Synopsis
Trial Summary
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: